Skip to main content
Top
Published in: Pathology & Oncology Research 2/2010

01-06-2010

Proximal-Type Epithelioid Sarcoma in the Groin Presenting as a Diagnostic Dilemma

Authors: Abul Ala Syed Rifat Mannan, Amre A. Rifaat, Mirza Kahvic, Kusum Kapila, Mrinmay Mallik, Vinod Kumar Grover, Chandramouli Bharati, Arie Perry

Published in: Pathology & Oncology Research | Issue 2/2010

Login to get access

Abstract

Epithelioid sarcoma is an uncommon soft-tissue sarcoma typically presenting as a subcutaneous or deep dermal mass in the distal extremities of young adults. Lately, a ‘proximal’ subtype has been described, which occurs in the pelvic and genital areas of somewhat older individuals and tends to behave more aggressively than the conventional subtype. The correct diagnosis of this subtype is essential, since this tumor can be easily mistaken for other malignant tumors that exhibit epithelioid morphology. We report a case of proximal-type epithelioid sarcoma that presented as an inguinal mass in a 47-year-old man. Histologically, the tumor consisted of diffuse sheets of epithelioid cells with scattered rhabdoid morphology. By immunohistochemistry, the neoplastic cells expressed cytokeratin, epithelial membrane antigen, vimentin, CD34, CD99 and showed complete loss of nuclear INI1 protein expression. Fluorescence in situ hybridization was considered borderline for 22q deletion. We present this case to emphasize the importance of diagnosing this uncommon tumor and the role of INI1 immunohistochemistry in establishing the diagnosis.
Literature
1.
go back to reference Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD (1997) “Proximal-type” epithelioid sarcoma: a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 21:130–146CrossRefPubMed Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD (1997) “Proximal-type” epithelioid sarcoma: a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 21:130–146CrossRefPubMed
2.
go back to reference Roberts CW, Orkin SH (2004) The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 4:133–142PubMed Roberts CW, Orkin SH (2004) The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 4:133–142PubMed
3.
go back to reference Versteege I, Sevenet N, Lange J et al (1998) Truncating mutation of hSNF5/INI1 in aggressive pediatric cancer. Nature 394:203–206CrossRefPubMed Versteege I, Sevenet N, Lange J et al (1998) Truncating mutation of hSNF5/INI1 in aggressive pediatric cancer. Nature 394:203–206CrossRefPubMed
4.
go back to reference Rousseau-Merck MF, Versteege I, Legrand I et al (1999) hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59:3152–3156PubMed Rousseau-Merck MF, Versteege I, Legrand I et al (1999) hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59:3152–3156PubMed
5.
go back to reference Biegel JA, Kalpana G, Knudsen ES et al (2002) The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62:323–328PubMed Biegel JA, Kalpana G, Knudsen ES et al (2002) The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62:323–328PubMed
6.
go back to reference Hoot AC, Russo P, Judkins AR et al (2004) Immunohistochemical analysis of the hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Sug Pathol 28:1485–1491CrossRef Hoot AC, Russo P, Judkins AR et al (2004) Immunohistochemical analysis of the hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Sug Pathol 28:1485–1491CrossRef
7.
go back to reference Sigauke E, Rakheja D, Maddox DL et al (2006) Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol 19:717–725CrossRefPubMed Sigauke E, Rakheja D, Maddox DL et al (2006) Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol 19:717–725CrossRefPubMed
8.
go back to reference Perry A, Fuller CE, Judkins AR, Dehner LP, Biegel JA (2005) INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol 18:951–958CrossRefPubMed Perry A, Fuller CE, Judkins AR, Dehner LP, Biegel JA (2005) INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol 18:951–958CrossRefPubMed
9.
go back to reference Modena P, Lualdi E, Facchinetti F et al (2005) SMARCB1/INI1 Tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 65:4012–4019CrossRefPubMed Modena P, Lualdi E, Facchinetti F et al (2005) SMARCB1/INI1 Tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 65:4012–4019CrossRefPubMed
10.
go back to reference Hornick JL, Dal Cin P, Fletcher CD (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33:542–550CrossRefPubMed Hornick JL, Dal Cin P, Fletcher CD (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33:542–550CrossRefPubMed
11.
go back to reference Chbani L, Guillou L, Terrier P et al (2009) Epithelioid sarcoma: a clinicopathologic and immunohistochemical study of 106 cases from the French sarcoma group. Am J Clin Pathol 131:22–27CrossRef Chbani L, Guillou L, Terrier P et al (2009) Epithelioid sarcoma: a clinicopathologic and immunohistochemical study of 106 cases from the French sarcoma group. Am J Clin Pathol 131:22–27CrossRef
12.
go back to reference Kohashi K, Izumi T, Oda Y et al (2009) Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 40:349–355CrossRefPubMed Kohashi K, Izumi T, Oda Y et al (2009) Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 40:349–355CrossRefPubMed
13.
go back to reference Enzinger FM (1970) Epithelioid sarcoma: a sarcoma simulating a granuloma or carcinoma. Cancer 26:1029–1041CrossRefPubMed Enzinger FM (1970) Epithelioid sarcoma: a sarcoma simulating a granuloma or carcinoma. Cancer 26:1029–1041CrossRefPubMed
14.
go back to reference Hasegawa T, Matsuno Y, Shimoda T, Umeda T, Yokoyama R, Hirohashi S (2001) Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases. Mod Pathol 14:655–663CrossRefPubMed Hasegawa T, Matsuno Y, Shimoda T, Umeda T, Yokoyama R, Hirohashi S (2001) Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases. Mod Pathol 14:655–663CrossRefPubMed
15.
go back to reference Daimaru Y, Hashimoto H, Tsuneyoshi M, Enjoji M (1987) Epithelial profile of epithelioid sarcoma. An immunohistochemical analysis of eight cases. Cancer 59:134–141CrossRefPubMed Daimaru Y, Hashimoto H, Tsuneyoshi M, Enjoji M (1987) Epithelial profile of epithelioid sarcoma. An immunohistochemical analysis of eight cases. Cancer 59:134–141CrossRefPubMed
16.
go back to reference Billings SD, Folpe AL, Weiss SW (2003) Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 27:48–57CrossRefPubMed Billings SD, Folpe AL, Weiss SW (2003) Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 27:48–57CrossRefPubMed
17.
go back to reference Raoux D, Peoch M, Pedeutour F et al (2009) Primary epithelioid sarcoma of bone. Report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol 33:954–958CrossRefPubMed Raoux D, Peoch M, Pedeutour F et al (2009) Primary epithelioid sarcoma of bone. Report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol 33:954–958CrossRefPubMed
18.
go back to reference Fanburg-Smith JC, Hengge M, Hengge UR, Smith JS Jr, Miettinen M (1998) Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 2:351–362CrossRefPubMed Fanburg-Smith JC, Hengge M, Hengge UR, Smith JS Jr, Miettinen M (1998) Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 2:351–362CrossRefPubMed
19.
go back to reference Oda Y, Tsuneyoshi M (2006) Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 56:287–295CrossRefPubMed Oda Y, Tsuneyoshi M (2006) Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol Int 56:287–295CrossRefPubMed
20.
go back to reference Rekhi B, Gorad BD, Chinoy RF (2008) Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India. Virchows Arch 453:141–153CrossRefPubMed Rekhi B, Gorad BD, Chinoy RF (2008) Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India. Virchows Arch 453:141–153CrossRefPubMed
21.
go back to reference Chase DR (1997) Do “rhabdoid features” impart a poorer prognosis to proximal-type epithelioid sarcomas? Commentary. Adv Anat Pathol 5:293–295CrossRef Chase DR (1997) Do “rhabdoid features” impart a poorer prognosis to proximal-type epithelioid sarcomas? Commentary. Adv Anat Pathol 5:293–295CrossRef
22.
go back to reference Livi L, Shah N, Paiar F, Fisher C, Judson I, Moskovic E et al (2003) Treatment of epithelioid sarcoma at Royal Marsden Hospital. Sarcoma 7:149–152CrossRefPubMed Livi L, Shah N, Paiar F, Fisher C, Judson I, Moskovic E et al (2003) Treatment of epithelioid sarcoma at Royal Marsden Hospital. Sarcoma 7:149–152CrossRefPubMed
23.
go back to reference Suit HD, Russell WO, Martin RG (1975) Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer 35:1478–1483CrossRefPubMed Suit HD, Russell WO, Martin RG (1975) Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer 35:1478–1483CrossRefPubMed
24.
go back to reference Onol FF, Tanidir Y, Kotiloğlu E, Bayramiçli M, Turhal S, Türkeri LN (2006) Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention. Eur Urol 49:406–407CrossRefPubMed Onol FF, Tanidir Y, Kotiloğlu E, Bayramiçli M, Turhal S, Türkeri LN (2006) Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention. Eur Urol 49:406–407CrossRefPubMed
Metadata
Title
Proximal-Type Epithelioid Sarcoma in the Groin Presenting as a Diagnostic Dilemma
Authors
Abul Ala Syed Rifat Mannan
Amre A. Rifaat
Mirza Kahvic
Kusum Kapila
Mrinmay Mallik
Vinod Kumar Grover
Chandramouli Bharati
Arie Perry
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9203-8

Other articles of this Issue 2/2010

Pathology & Oncology Research 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine